Dovato allows patients to reduce the number of antiretrovirals (ARVs) that they take, whilst maintaining the efficacy of three-drug regimens in a single-pill regimen.
ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the Scottish Medicines Consortium (SMC) has issued positive advice for Dovato (dolutegravir/lamivudine) for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine.
It means that from today, appropriate adult patients in Scotland can access this new treatment – the first UK patients to be given this additional option.
Dr Rak Nandwani, Chair of the Scottish HIV Clinical Leads said: “Owing to treatment advances, people living with HIV are healthier and living longer than ever before. Individuals with undetectable viral load cannot pass it on. I’m pleased that Scotland continues to lead the way in the UK in terms of providing new options to both prevent and treat HIV. The SMC decision for Dovato offers a new type of treatment option with fewer agents compared to the current standard of taking a daily three drug regimen. Dovato also has the potential to offer further cost savings to NHS Scotland, in addition to the large savings which we have managed to achieve in recent years.”
Dovato is a once-daily, single-tablet, two-drug regimen that combines the integrase strand transfer inhibitor, dolutegravir, with the nucleoside analogue reverse transcriptase inhibitor, lamivudine.
Deborah Whitehouse, Country Manager of ViiV UK, said: “It’s our ambition to reduce the number of HIV drugs people living with HIV take over a lifetime. Today’s SMC decision means that people living with HIV in Scotland can for the first time start treatment on a once-daily, single-pill, two-drug regimen with the knowledge that it has been shown to be as effective as a three-drug regimen whilst containing fewer antiretrovirals.”